UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in NewAmsterdam Pharma (NASDAQ:NAMS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 253,571 shares of the company's stock after buying an additional 14,288 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.27% of NewAmsterdam Pharma worth $6,517,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in NAMS. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $154,000. The Manufacturers Life Insurance Company bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $221,000. Finally, Keybank National Association OH bought a new position in NewAmsterdam Pharma during the 4th quarter valued at about $257,000. 89.89% of the stock is currently owned by institutional investors.

Insider Activity at NewAmsterdam Pharma

In other news, Director James N. Topper bought 1,135 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. The trade was a 0.04% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.84% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Price Performance

NAMS stock traded up $0.12 during mid-day trading on Thursday, reaching $19.51. The company had a trading volume of 1,080,203 shares, compared to its average volume of 657,960. The company has a market capitalization of $2.19 billion, a PE ratio of -10.38 and a beta of 0.01. The firm has a 50 day moving average of $17.75 and a 200 day moving average of $20.87. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. Analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

NAMS has been the topic of several analyst reports. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. Cantor Fitzgerald initiated coverage on shares of NewAmsterdam Pharma in a report on Wednesday. They set an "overweight" rating and a $42.00 price target on the stock. Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Friday, May 30th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $42.86.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.